EfficientMask-Net for face authentication in the era of COVID-19 pandemic.

Today, we are facing the COVID-19 pandemic. Accordingly, properly wearing face masks has become vital as an effective way to prevent the rapid spread of COVID-19. This research develops an Efficient Mask-Net method for low-power devices, such as mobile and embedding models with low-memory requirements. The method identifies face mask-wearing conditions in two different schemes: I. Correctly Face Mask (CFM), Incorrectly Face Mask (IFM), and Not Face Mask (NFM) wearing; II. Uncovered Chin IFM, Uncovered Nose IFM, and Uncovered Nose and Mouth IFM. The proposed method can also be helpful to unmask the face for face authentication based on unconstrained 2D facial images in the wild. In this study, deep convolutional neural networks (CNNs) were employed as feature extractors. Then, deep features were fed to a recently proposed large margin piecewise linear (LMPL) classifier. In the experimental study, lightweight and very powerful mobile implementation of CNN models were evaluated, where the novel "EffientNetb0" deep feature extractor with LMPL classifier outperformed well-known end-to-end CNN models, as well as conventional image classification methods. It achieved high accuracies of 99.53 and 99.64% in fulfilling the two mentioned tasks, respectively.

Organ-specific or personalized treatment for COVID-19: rationale, evidence, and potential candidates.

Although extrapulmonary manifestations of coronavirus disease 2019 (COVID-19) are increasingly reported, no effective therapeutic strategy for these multisystemic complications is available due to a poor understanding of the pathophysiology of COVID-19 multiorgan involvement. In this study, differentially expressed genes (DEGs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected extrapulmonary organs including human pluripotent stem cells (hPSCs)-derived liver organoids and choroid plexus organoids besides transformed lung alveolar (A549) cells were analyzed. First, pathway enrichment analysis was done to compare the underlying biological pathways enriched upon SARS-CoV-2 infection in different organs. Then, these lists of DEGs were used in a connectivity map (CMap)-based drug repurposing experiment. Also, protein-protein interaction (PPI) network analysis was done to compare the associated hub genes. The results revealed different biological pathways and genes responsible for SARS-CoV-2 multisystemic pathogenesis based on the organ involved that highlighted the need for considering organ-specific treatments or even personalized therapy. Besides, some FDA-approved drugs were proposed as the potential therapeutic candidates for each infected cell line.

De novo design of novel protease inhibitor candidates in the treatment of SARS-CoV-2 using deep learning, docking, and molecular dynamic simulations.

The main protease of SARS-CoV-2 is a critical target for the design and development of antiviral drugs. 2.5 M compounds were used in this study to train an LSTM generative network via transfer learning in order to identify the four best candidates capable of inhibiting the main proteases in SARS-CoV-2. The network was fine-tuned over ten generations, with each generation resulting in higher binding affinity scores. The binding affinities and interactions between the selected candidates and the SARS-CoV-2 main protease are predicted using a molecular docking simulation using AutoDock Vina. The compounds selected have a strong interaction with the key MET 165 and Cys145 residues. Molecular dynamics (MD) simulations were run for 150ns to validate the docking results on the top four ligands. Additionally, root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and hydrogen bond analysis strongly support these findings. Furthermore, the MM-PBSA free energy calculations revealed that these chemical molecules have stable and favorable energies, resulting in a strong binding with Mpro's binding site. This study's extensive computational and statistical analyses indicate that the selected candidates may be used as potential inhibitors against the SARS-CoV-2 in-silico environment. However, additional in-vitro, in-vivo, and clinical trials are required to demonstrate their true efficacy.

A large margin piecewise linear classifier with fusion of deep features in the diagnosis of COVID-19.

The world has experienced epidemics of coronavirus infections several times over the last two decades. Recent studies have shown that using medical imaging techniques can be useful in developing an automatic computer-aided diagnosis system to detect pandemic diseases with high accuracy at an early stage. In this study, a large margin piecewise linear classifier was developed to diagnose COVID-19 compared to a wide range of viral pneumonia, including SARS and MERS, using chest x-ray images. In the proposed method, a preprocessing pipeline was employed. Moreover, deep pre- and post-rectified linear unit (ReLU) features were extracted using the well-known VGG-Net19, which was fine-tuned to optimize transfer learning. Afterward, the canonical correlation analysis was performed for feature fusion, and fused deep features were passed into the LMPL classifier. The introduced method reached the highest performance in comparison with related state-of-the-art methods for two different schemes (normal, COVID-19, and typical viral pneumonia) and (COVID-19, SARS, and MERS pneumonia) with 99.39% and 98.86% classification accuracy, respectively.

A connectivity map-based drug repurposing study and integrative analysis of transcriptomic profiling of SARS-CoV-2 infection.

AIMS: The recent outbreak of COVID-19 has become a global health concern. There are currently no effective treatment strategies and vaccines for the treatment or prevention of this fatal disease. The current study aims to determine promising treatment options for the COVID-19 through a computational drug repurposing approach. MATERIALS AND METHODS: In this study, we focus on differentially expressed genes (DEGs), detected in SARS-CoV-2 infected cell lines including "the primary human lung epithelial cell line NHBE" and "the transformed lung alveolar cell line A549". Next, the identified DEGs are used in the connectivity map (CMap) analysis to identify similarly acting therapeutic candidates. Furthermore, to interpret lists of DEGs, pathway enrichment and protein network analysis are performed. Genes are categorized into easily interpretable pathways based on their biological functions, and overrepresentation of each pathway is tested in comparison to what is expected randomly. KEY FINDINGS: The results suggest the effectiveness of lansoprazole, folic acid, sulfamonomethoxine, tolnaftate, diclofenamide, halcinonide, saquinavir, metronidazole, ebselen, lidocaine and benzocaine, histone deacetylase (HDAC) inhibitors, heat shock protein 90 (HSP90) inhibitors, and many other clinically approved drugs as potent drugs against COVID-19 outbreak. SIGNIFICANCE: Making new drugs remain a lengthy process, so the drug repurposing approach provides an insight into the therapeutics that might be helpful in this pandemic. In this study, pathway enrichment and protein network analysis are also performed, and the effectiveness of some drugs obtained from the CMap analysis has been investigated according to previous researches.